肝细胞癌术后辅助治疗II期研究：37例患者1年无复发生存率59.7%、中位无复发生存15.6个月
《自然-通讯》发表的ALTER-H006 II期研究评估了benmelstobart联合anlotinib用于高复发风险肝细胞癌切除术后辅助治疗的效果。研究纳入37例患者，中位随访12.6个月。
结果显示，1年无复发生存率为59.7%，中位无复发生存期为15.6个月；1年总生存率为91.7%，中位总生存期尚未达到。最长无复发持续时间为25.9个月。
安全性方面，45.9%的患者出现3级及以上治疗相关不良事件，最常见为高血压，未出现治疗相关死亡。研究者表示，该方案显示出可行性，仍需大规模随机对照试验确认。
Phase II HCC Adjuvant Study in 37 Patients: 1-Year RFS 59.7%, Median RFS 15.6 Months
The phase II ALTER-H006 study published in Nature Communications evaluated adjuvant benmelstobart plus anlotinib in patients with high-risk recurrence after resection of hepatocellular carcinoma. The study enrolled 37 patients, with a median follow-up of 12.6 months.
The 1-year recurrence-free survival rate was 59.7%, and median recurrence-free survival was 15.6 months. The 1-year overall survival rate was 91.7%, with median overall survival not reached. The longest recurrence-free duration was 25.9 months.
Grade 3 or higher treatment-related adverse events occurred in 45.9% of patients, most commonly hypertension, and no treatment-related deaths occurred. The authors said the regimen is a feasible option warranting confirmation in large-scale randomized trials.
来源：《自然-通讯》
发布：GSM·美国（发布链接）
图片来源：肝细胞癌的病理切片图像。照片：Ed Uthman，CC BY 2.0，经 Wikimedia Commons / Hepatocellular carcinoma pathology. Photo: Ed Uthman, CC BY 2.0, via Wikimedia Commons
GSM Global · 本篇英文版 English edition of this story
